CMV then induces the production of leukotriene B4 in smooth muscle cells, which controls the function of matrix metallopeptidase (MMPs) in macrophages.
[6] In 2013, she identified that by treating the CMV, through an antiviral used as a supplement to oncological therapies, could extend the survival time of glioblastoma patients.
[5][7] She showed that the simple antiviral treatment Valganciclovir could extend the life expectancy of glioblastoma patients by forty months.
[5][8] She is leading a double-blind clinical trial to evaluate the efficacy of valganciclovir, an anti-CMV drug, in the treatment of patients with glioblastoma.
[11][15][14] In an interview with The Guardian, Söderberg-Nauclér accused the Swedish government of "thinking they can’t stop it, so they’ve decided to let people die”.